




## N<sup>6</sup>-(6-Aminoethyl)-ATP

N<sup>6</sup>-(6-Aminoethyl)-adenosine-5'-triphosphate, Sodium salt

Cat. No.	Amount
NU-805S	50 µl (10 mM)
NU-805L	5 x 50 µl (10 mM)



Structural formula of N<sup>6</sup>-(6-Aminoethyl)-ATP

### For general laboratory use.

**Shipping:** shipped on gel packs

**Storage Conditions:** store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

**Shelf Life:** 12 months after date of delivery

**Molecular Formula:** C<sub>16</sub>H<sub>29</sub>N<sub>6</sub>O<sub>13</sub>P<sub>3</sub> (free acid)

**Molecular Weight:** 606.36 g/mol (free acid)

**Exact Mass:** 606.10 g/mol (free acid)

**CAS#:** 53602-93-0

**Purity:** ≥ 95 % (HPLC)

**Form:** solution in water

**Color:** colorless to slightly yellow

**Concentration:** 10 mM - 11 mM

**pH:** 7.5 ± 0.5

**Spectroscopic Properties:** λ<sub>max</sub> 266 nm, ε 16.2 L mmol<sup>-1</sup> cm<sup>-1</sup> (Tris-HCl pH 7.5)

### Applications:

Agonistic ligand, mainly for nucleoside receptor A<sub>1</sub>. Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands. In some cases nucleoside phosphates act also directly on nucleoside receptors.

### Specific Ligands:

Myosin V<sup>[1]</sup>

### Selected References:

[1] Komori *et al.* (2008) Measurement system for simultaneous observation of myosin V chemical and mechanical events. *BioSystems* **93**:48.

[2] Williamson *et al.* (2009) Novel adenosine derived inhibitors of 70 kDa Heat Shock Protein, discovered through structure based design. *J. Med. Chem.* **52**:1510.

[3] Teramoto *et al.* (2000) In vitro selection of a ligase ribozyme carrying alkylamino groups in the side chains. *Bioconjugate Chem.* **11**:744.

[4] Folsom *et al.* (1989) Detection of DNA targets with biotinylated and fluoresceinated RNA probes. Effect of the extent of derivatization on detection sensitivity. *Analytic. Biochem.* **182**:309.

Sirci *et al.* (2012) Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> receptor antagonists. *J. Comput. Aided Mol. Des.* **26**:1247.

Volonte *et al.* (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. *FEBS J.* **276**:318.

Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* **1783**:673.

Joshi *et al.* (2005) Purine derivatives as ligands for A<sub>3</sub> adenosine receptors. *Current Topics in Medicinal Chemistry* **5**:1275.

Hess (2001) Recent advantages in adenosine receptor antagonist research. *Expert Opin. Ther. Patents* **11** (10):1533.

Jacobson (2001) Probing adenosine and P<sub>2</sub> receptors: design of novel purines and nonpurines as selective ligands. *Drug Development Res.* **52**:178.

Jacobson *et al.* (2001) Ribose modified nucleosides and nucleotides as ligands for purine receptors. *Nucleosides, Nucleotides & Nucleic Acids* **20** (4):333.

Ito *et al.* (1998) Modified nucleic acid for systematic evolution of RNA ligands by exponential enrichment. *J. Bioact. Compat. Pol.* **13** (2):114.

Trayer (1974) Affinity chromatography of some adenosine phosphate-requiring systems. *Biochem. Soc. T.* **2** (6):1302.

Van Galen *et al.* (1994) A binding site model and structure-activity relationships

**N<sup>6</sup>-(6-Aminoethyl)-ATP**N<sup>6</sup>-(6-Aminoethyl)-adenosine-5'-triphosphate, Sodium salt

for rat A3 adenosine receptor. *Molecular Pharmacology* **45**:1101.

Trayer *et al.* (1974) Preparation of adenosine nucleotide derivatives suitable for affinity chromatography. *Biochem. J.* **139** (3):609.